Eli Lilly (LLY) Acquisitions (2010 - 2022)

Eli Lilly has reported Acquisitions for 11 years, with the latest figure at $327.2 million in Q4 2022.

• For the quarter ending Q4 2022, Acquisitions changed N/A year-over-year to $327.2 million; the trailing twelve-month figure through Dec 2022 stood at $327.2 million (down 56.22% YoY), and the FY2022 full-year result was $327.2 million, down 56.22% from the prior year.
• Acquisitions for Q4 2022 stood at $327.2 million, down from $747.4 million in the prior quarter.
• The five-year high for Acquisitions was $6.9 billion in Q1 2019, with the low at $327.2 million in Q4 2022.
• Historically, Acquisitions has averaged $2.2 billion across 4 years, with a median of $798.3 million in 2020.
• Annual changes were most pronounced in 2020 — Acquisitions sank 87.72% — and 2021, when it slipped 12.0%.
• Eli Lilly's Acquisitions stood at $6.9 billion in 2019, then slumped by 87.72% to $849.3 million in 2020, then decreased by 12.0% to $747.4 million in 2021, then plunged by 56.22% to $327.2 million in 2022.
• The last three Acquisitions figures came in at $327.2 million (Q4 2022), $747.4 million (Q1 2021), and $849.3 million (Q1 2020), per Business Quant data.